MarketInOut Stock Screener Log In | Sign Up
 

Sutro Biopharma Inc

NASDAQ • Healthcare • Biotechnology • Quote as of 10/23/2026
Sutro Biopharma Inc stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization178.91 mln
Float14.37 mln
Earnings Date11/11/2026

Piotroski F-Score

2 / 9
Weak

Beneish M-Score

-2.65
Likely reliable

Relative Strength

5 / 100
Severely lagging

Pre-Tax Margin

-395%
Severely loss-making

ROE

185
Extraordinary

Altman Z-Score

-8.48
Deeply distressed

Business Description

Sutro Biopharma is a California-based biotechnology company focused on developing advanced cancer treatments and vaccines. Its core work centers on a proprietary cell-free protein synthesis technology used to create a new generation of antibody-drug conjugates, which are precision medicines designed to target and destroy cancer cells while minimizing harm to healthy tissue. The company's cancer pipeline targets a range of solid tumors and blood cancers, while its vaccine programs address serious infectious diseases such as pneumococcal illness. Sutro works alongside several major pharmaceutical partners, including Ipsen, Astellas, and Vaxcyte, to bring these therapies to patients around the world.

Key Fundamentals

EPS-16.16
ROE185
RPS3.91
ROIC-220
ROA-83.45
Interest Cover-3.53
EBITDA, mln-136
EV / EBITDA-2.59
EV / EBIT-2.48
Revenue, mln45.70
EV / Revenue7.71

Quote Details

Last 9.33
Change -0.96 (-9.33%)
Open 10.22
Volume 430,831
Turnover 4,019,653
Average Volume 305,729

Financial Ratios

Pre-Tax Profit Margin-395
Current Ratio3.32
Price / Sales3.88

Financial Strength

Altman Z-Score-8.48
Piotroski F-Score 2 / 9
Beneish M-Score-2.65
Short Ratio5.93
Short % of Float11.18

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week -14.72% 5 / 100   
1 Month -40.61% 7 / 100   
2 Months -58.7% 6 / 100   
6 Months -72.01% 6 / 100   
1 Year -19.57% 30 / 100   



Disclaimer - Privacy Policy - Terms Of Service - Cookie Use Policy - FAQ - Blog